Ultra low molecular weight heparin: Difference between revisions
Jump to navigation
Jump to search
(New page: '''Editors-in-Chief:''' C. Michael Gibson, M.S., M.D. '''Associate Editor-In-Chief''': Ujjwal Rastogi, MBBS [mailto:urastogi@perfuse.org] {{Deep vein thrombos...) |
m (Protected "Ultra low molecular weight heparin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Editors-in-Chief:''' [[C. Michael Gibson, M.S., M.D.] | '''Editors-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]] | ||
{{ | ==Overview== | ||
AVE5026 is a hemisynthetic, ultra low molecular weight heparin. It is obtained by highly selective and controlled depolymerization of heparin. It has an average molecular weight of 2000 to 3000 Da, as compared to 4000 to 5000 Da of other LMW heparins. | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Anticoagulants]] | |||
Latest revision as of 18:52, 27 September 2011
Editors-in-Chief: C. Michael Gibson, M.S., M.D.
Overview
AVE5026 is a hemisynthetic, ultra low molecular weight heparin. It is obtained by highly selective and controlled depolymerization of heparin. It has an average molecular weight of 2000 to 3000 Da, as compared to 4000 to 5000 Da of other LMW heparins.